SEC Form 4 · accession 0001209191-17-003344
Conatus Pharmaceuticals Inc. · CNAT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles Cashion
Officer — SVP, Finance, CFO and Sec.
Period of report
Jan 9, 2017
Accepted (ET)
Jan 11, 2017 · 4:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001383701
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 9, 2017 | M | 42,424 | $0.99 | A | 42,424 | D | |
| Common StockF1 | holding | — | — | — | 144,738 | I | See footnote. |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $0.99 | Jan 9, 2017 | M | 42,424 | D | Feb 17, 2011 | Feb 16, 2021 | Common Stock | 42,424 | 0 | D |
Explanation of responses
- F1Held in a trust of which Mr. Cashion is a trustee.